BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Biotech Bay

  Plexium Raises $102 Million to Advance Protein Degradation Pipeline

  Plexium raised millions for its multi-year research collaboration and license deal with Amgen to identify novel targeted protein degradation therapeutics.

  February 23, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Three Biopharma Companies Bolster Leadership Teams

  Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.

  February 23, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Experimental MDD Drug Esmethadone Appears Less Addictive than Ketamine

  Studies of Relmada’s drug, esmethadone, showed the drug had lower human abuse potential when compared to ketamine. Here are the results of this study.

  February 23, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Global Roundup: NuCana’s Biliary Tract Cancer Drug, Charles River, Noema and More

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  February 23, 2022

   · 

  6 min read

   · 

  Alex Keown
• 

  Business

  Veru/Lilly Aim to Fill Gap in Second-Line Metastatic Breast Cancer Therapy

  Veru’s enobosarm shows good proof of concept data even when 90% of patients have failed first-line therapies.

  February 23, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Drug Development

  Kodiak Fails to See Endpoint vs. Regeneron’s Eylea in Wet AMD

  Shares of Kodiak Sciences plunged nearly 70% in premarket trading after its Phase II/III study of KSI-301 failed to demonstrate non-inferior visual acuity gains compared to Regeneron’s Eylea.

  February 23, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Moderna Cleared to Bring RSV Vaccine to Pivotal Phase III Trial

  The DSMB endorsed the use of mRNA-1345 for the Phase III ConquerRSV study following positive preliminary Phase II data that demonstrates the vaccine’s safety profile.

  February 23, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Sanofi and GSK Prepare to Submit COVID-19 Vaccine as Cases Fall

  Public health officials begin to think we’ve turned the corner on the pandemic as new global cases drop 21% last week, the third consecutive week numbers and deaths have declined.

  February 23, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Why Communication Skills Are So Important In Pharma

  Effective communication skills are vital for success in the pharma industry. Here are some tips to help you improve your communication skills.

  February 23, 2022

   · 

  5 min read

   · 

  Mishayl Hanan
• 

  Business

  Biopharma Giants Make Big Manufacturing Commitments

  Intellia announced a lease agreement to develop a 140,000 square-foot manufacturing facility in Waltham, MA, while Moderna and Thermo Fisher Scientific sign a long-term deal.

  February 23, 2022

   · 

  2 min read

   · 

  Hayley Shasteen